Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 7, 2003 - Issue 3
Submit an article Journal homepage
141
Views
93
CrossRef citations to date
0
Altmetric
Review

Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects

Barbara Fingleton Vanderbilt University Medical Center, Department of Cancer Biology, 736 PRB 23rd and Pierce Avenues, Nashville, TN 37232-6840, USA
Pages 385-397 | Published online: 02 Mar 2005

Bibliography

  • EGEBLAD M, WERB Z: New functions forthe matrix metalloproteinases in cancer progression. Nat. Rev Cancer (2002) 2:161–174.
  • ••Comprehensive and well-written review ofhow non-matrix substrates expand the roles for MMPs in cancer.
  • MCCAWLEY LJ, MATRISIAN LM: Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. (2001) 13:534–540.
  • WOESSNER JF, NAGASE H:Matrix Metalloproteinases and TIMPs. Oxford University Press, Inc., New York (2000).
  • • Excellent book reviewing multiple aspects of MMP and TIMP biology.
  • BIGG HF, ROWAN AD: The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis. Curr. Opin. Pharmacol (2001) 1:314–320.
  • SHAPIRO SD: Diverse roles of macrophage matrix metalloproteinases in tissue destruction and tumor growth. Thromb. Haernast. (1999) 82:846–849.
  • GALIS ZS, KHATRI JJ:Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. (2002) 90:251–262.
  • LEPPERT D, LINDBERG RL, KAPPOS L, LEIB SL: Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Rev (2001) 36:249–257.
  • INGMAN T, TERVAHARTIALA T, DING Y et al: Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. Periodontol (1996) 23:1127–1132.
  • LIOTTA LA, TRYGGVASON K, GARBISA S, HART I, FOLTZ CM, SHAFIE S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (1980) 284:67–68.
  • • A classic paper linking MMP activity and tumour cell invasion.
  • SCORILAS A, KARAMERIS A,ARNOGIANNAKI N et al: Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer (2001) 84:1488–1496.
  • GORRIN RIVAS MJ, ARII S,FURUTANI M et al: Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology (1998) 28:986–993.
  • YANG W, ARII S, GORRIN-RIVAS MJ, MORI A, ONODERA H, IMAMURA M: Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer (2001) 91:1277–1283.
  • KUITTINEN 0, SOINI Y, TURPEENNIEMI-HUJANEN T: Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur. Haernatol (2002) 69:205–212.
  • COUSSENS LM, TINKLE CL, HANAHAN D, WERB Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 103:481–490.
  • CHAMBERS AF, MATRISIAN LM: Changing views of the role of matrix metalloproteinases in metastasis. J. Nati Cancer Inst. (1997) 89:1260–1270.
  • WOLF K, MAZO I, LEUNG H et al.: Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. (2003) 160:267–277.
  • ••Excellent study that carefully dissectsmechanisms of cell migration in vivo.
  • LIOTTA L: Tumor invasion and metastasis - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. (1986) 46:1–7.
  • STERNLICHT MD, BERGERS G: Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerg. Ther. Targets (2000) 4:609–633.
  • •One of the most comprehensive and thoughtful reviews of MMPs and MMPIs.
  • STERNLICHT MD, LOCHTER A,SYMPSON CJ et al.: The stromal proteinase
  • ••MMP3/stromelysin-1 promotes mammarycarcinogenesis. Cell (1999) 98:137–146.
  • HA HY, MOON HB, NAM MS et al.: Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res. (2001) 61:984–990.
  • ITOH T, TANIOKA M, YOSHIDA H, YOSHIOKA T, NISHIMOTO H, ITOHARA S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. (1998) 58:1048–1051.
  • WILSON CL, HEPPNER KJ, LAB OSKY PA, HOGAN BLM, MATRISIAN LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Nati Acad. Sci. USA (1997) 94:1402–1407.
  • ITOH T, TANIOKA M, MATSUDA H et al.: Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis (1999) 17:177–181.
  • MASSON R, LEFEBVRE 0, NOEL A et al.: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. (1998) 140:1535–1541.
  • BERGERS G, JAVAHERIAN K, LO KM, FOLKMAN J, HANAHAN D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 284:808–812.
  • •Illustrates the importance of tumour stage for efficacy of angiogenesis inhibitors.
  • COUSSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295:2387–2392.
  • WYNN RL: Latest FDA approvals for dentistry. Gen. Dent. (1999) 47:19–22.
  • BROWN PD: Ongoing trials with matrixmetalloproteinase inhibitors. Expert. Opin. Investig. Drugs (2000) 9:2167–2177.
  • BATIST G, PATENAUDE F,CHAMPAGNE P et al: Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann. Oncol. (2002) 13:1259–1263.
  • LEVITT NC, ESKENS FA, O'BYRNE KJ et al.: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CG527023A), in patients with advanced solid cancer. Clin. Cancer Res. (2001) 7:1912–1922.
  • NEMUNAITIS J, POOLE C,PRIMROSE J et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. (1998) 4:1101–1109.
  • GORE M, A'HERN R,STANKIEWICZ M, SLEVIN M: Tumour marker levels during marimastattherapy. Lancet (1996) 348:263–264.
  • WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al.: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Clin. Oncol. (1998) 16:2150–2156.
  • CIANFROCCA M, COOLEY TP, LEE JY et al.: Matrix metalloproteinase inhibitor Col-3 in the treatment of AIDS-related Kaposi's sarcoma: a Phase I AIDS malignancy consortium study. J. Clin. Oncol (2002) 20:153–159.
  • HIRTE H, GOEL R, BENNETT K: Phase I study of the matrix metalloproteinase inhibitor BAY-12-9566 in patients with advanced cancer. Ann. Oncol (1998) 9\(Suppl. 2):Abstract 286.
  • VON HOFF DD: There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. (1998) 4:1079–1086.
  • KORN EL, ARBUCK SG, PLUDA JM, SIMON R, KAPLAN RS,CHRISTIAN MC: Clinical trial designs for cytostatic agents: are new approaches needed?' Clin. Oncol. (2001) 19:265–272.
  • BREMER C, TUNG CH,WEISSLEDER R: In vivo molecular targetassessment of matrix metalloproteinase inhibition. Nat. Med. (2001) 7:743–748.
  • •Important study demonstrating in vivo MMP inhibition by a MMPI.
  • BREMER C, TUNG CH,BOGDANOV AJR, WEISSLEDER R: Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology (2002) 222:814–818.
  • TUNG CH, MAHMOOD U, BRED OW S, WEISSLEDER R: In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. (2000) 60:4953–4958.
  • MARTEN K, BREMER C, KHAZAIE K et al.: Detection of dysplastic intestinaladenomas using enzyme-sensing molecular beacons in mice. Gastroenterology (2002) 122:406–414.
  • WEISSLEDER R, MAHMOOD U: Molecular imaging. Radiology (2001) 219:316–333.
  • ••An excellent review covering current andpotential molecular imaging strategies.
  • LOUIE AY, HUBER MM, AHRENS ET et al.: In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnol. (2000) 18:321–325.
  • ZHENG QH, FEI X, LIU X et al.: Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl. Med. Biol. (2002) 29:761–770.
  • POWELL WC, FINGLETON B, WILSON CL, BOOTHBY M, MATRISIAN LM: The metalloproteinase matrilysin (MMP-7) proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curt: Biol. (1999) 9:1441–1447.
  • MITSIADES N, YU W, POULAKI V, TSOKOS M, STAMENKOVIC I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. (2001) 61:577–581.
  • NOE V, FINGLETON B, JACOBS K et al: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. Cell Sci. (2001) 114:111–118.
  • LOCHTER A, GALOSY S,MUSCHLER J, FREEDMAN N, WERB Z, BISSELL MJ:Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. (1997) 139:1861–1872.
  • MIZUTANI Y, YOSHIDA 0, UKIMURA 0, KAWAUCHI A, BONAVIDA B, MIKI T: Prognostic significance of a combination of soluble fas and soluble fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother. Radiopharm. (2002) 17:563–567.
  • GARCIA-VELASCO JA, MULAYIM N, KAYISLI UA, ARICI A: Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis. Feral. Steril. (2002) 78:855–859.
  • CHAN AO, LAM SK, CHU KM et al.: Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut (2001) 48:808–811.
  • KARAYIANNAKIS AJ, SYRIGOS KN, SAVVA A, POLYCHRONIDIS A, KARATZAS G, SIMOPOULOS C: Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy. Surg. Endosc. (2002) 16:1551–1554.
  • MCQUIBBAN GA, GONG JH, WONG JP, WALLACE JL, CLARK-LEWIS I, OVERALL CM: Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 100:1160–1167.
  • MCQUIBBAN GA, GONG JH, TAM EM, MCCULLOCH CA, CLARK-LEWIS I, OVERALL CM: Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science (2000) 289:1202–1206.
  • LOPEZ-OTIN C, OVERALL CM: Protease degradomics: a new challenge for proteomics. Nat. Rev Mol. Cell Biol. (2002) 3:509–519.
  • KERBEL RS: What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev. (1998) 17:301–304.
  • FIDLER IJ: Host and tumour factors in cancer metastasis. Eur. Clin. Invest. (1990) 20:481–486.
  • MACLEOD KF, JACKS T: Insights into cancer from transgenic mouse models. Pathol. (1999) 187:43–60.
  • SCHATZKIN A, GAIL M: The promise and peril of surrogate end points in cancer research. Nat. Rev Cancer (2002) 2:19–27.
  • •Important concepts for clinical trials.
  • BRAMHALL SR, HALLISSEY MT, WHITING J et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer (2002) 86:1864–1870.
  • ••The first Phase III trial result to indicatethat MMPIs may be efficacious in the appropriate setting.
  • MATRISIAN LM, BOWDEN GT, KRIEG P et al.: The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors. Proc. Natl. Acad. Sci. USA (1986) 83:9413–9417.
  • MULLER D, QUANTIN B,GESNEL MC, MILLON-COLLARD R, ABECASSIS J, BREATHNACH R: The collagenase gene family in humans consists of at least four members. Biochem. (1988) 253:187–192.
  • BASSET P, BELLOCQ JP, WOLF C et al: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (1990) 348:699–704.
  • ARLT M, KOPITZ C, PENNINGTON C et al.: Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res. (2002) 62:5543–5550.
  • NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. (2000) 18:1135–1149.
  • FINGLETON B, MATRISIAN LM: Matrix metalloproteinases in cancer. In: Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy. NJ Clendeninn, K Appelt (Eds), Humana Press, Inc., Totowa, NJ (2000):85–112.
  • GIRANDA VL, MATRISIAN LM: The protease consortium: an alliance to advance the understanding of proteolytic enzymes as therapeutic targets for cancer. Mol. Carcinog. (1999) 26:139–142.
  • MCKERROW JH, BHARGAVA V, HANSELL E et al.: A functional proteomics screen of proteases in colorectal carcinoma. Mol. Med. (2000) 6:450–460.
  • •A novel approach to profiling multiple proteases in tumour samples.
  • BRAMHALL SR, SCHULZ J,NEMUNAITIS J, BROWN PD,BAILLET M, BUCKELS JA:A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. BE J. Cancer (2002) 87:161–167.
  • •A MMPI Phase III trial indicating possible efficacy in non-metastatic disease.
  • MILLER KD, GRADISHAR WJ, SCHUCHTER LM et al: A randomized Phase II pilot trial of adjuvant marimastat in patients with early breast cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:Abstract 369.
  • DEGEORGE JJ, AHN CH, ANDREWS PA et al: Regulatoryconsiderations for preclinical development of anticancer drugs. Cancer Chemother. Pharmacol. (1998) 41:173–185.
  • GOEL R, HIRTE H, SHAH A et al: Phase I study of the metalloproteinase inhibitor Bayer 12–9566. Proc. Am. Soc. Clin. Oncol. (1998) 17:Abstract 840.
  • RUTTER JL, MITCHELL TI,BUTTICE G et al: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. (1998) 58:5321–5325.
  • BRINCKERHOFF CE, RUTTER JL, BENBOW U: Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. (2000) 6:4823–4830.
  • HURWITZ H, HUMPHREY J, WILLIAMS K et al.: A phase I trial of BMS-275291: a novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMPI) with no dose-limiting arthritis. Proc. Am. Soc. Clin. Oncol. (2001) 20:Abstract 387.
  • SEALS DF, COURTNEIDGE SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. (2003) 17:7–30.
  • DRUMMOND AH, BECKETT P, BROWN PD etal.: Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. (1999) 878:228–235.
  • TANG BL: ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. (2001) 33:33–44.
  • COLIGE A, SIERON AL, LI SW et al.: Human Ehlers-Danlos syndromeType VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. Am. J. Hum. Genet. (1999) 65:308–317.
  • •Important study linking an ADAM-TS deficiency with human disease.
  • FERNANDES RJ, HIROHATA S, ENGLE JM et al: Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. J. Biol. Chem. (2001) 276:31502–31509.
  • COLIGE A, VANDENBERGHE I, THIRY M et al: Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. j Biol. Chem (2002) 277:5756–5766.
  • TORTORELLA MD, BURN TC, PRATTA MA etaL: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 284: 1664-1666.
  • TORTORELLA MD, LIU RQ, BURNT, NEWTON RC, ARNER E: Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol. (2002) 21:499–511.
  • KASHIWAGI M, TORTORELLA M, NAGASE H, BREW K: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).J. Biol. Chem. (2001) 276:12501–12504.
  • AMOUR A, KNIGHT CG, WEBSTER A et al.: The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. (2000) 473:275–279.
  • MURPHY G, KNAUPER V, COWELL S et al: Evaluation of some newer matrix metalloproteinases. Ann. NY Acad. Li. (1999) 878:25–39.
  • HOLMBECK K, BIANCO P, CATERINA J et al: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 99:81–92.
  • •The first severe phenotype in a MMP-null mouse.
  • ZHOU Z, APTE SS, SOININEN R et al.: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Nati Acad. Li. USA (2000) 97:4052–4057.
  • •Confirmation of the MMP-14-null phenotype.
  • MARTIGNETTI JA, AQEEL AA, SEWAIRI WA et al.: Mutation of the matrix metalloproteinase 2 gene (IVIMP2) causes a multicentric osteolysis and arthritis syndrome. Nat. Genet. (2001) 28:261–265.
  • ••Important paper describing thephenotype associated with a MMP deficiency in humans.
  • ITOH T, IKEDA T, GOMI H, NAKAO S, SUZUKI T, ITOHARA S:Unaltered secretion of 13-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J. Biol. Chem. (1997) 272:22389–22392.
  • KOIVUNEN E, ARAP W, VALTANEN H et al: Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol (1999) 17:768–774.
  • BERNARDO MM, BROWNS, LI ZH, FRIDMAN R, MOBASHERY S:Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J. Biol. Chem. (2002) 277:11201–11207.
  • OVERALL CM, LOPEZ-OTIN C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev Cancer (2002) 2:657–672.
  • MURRAY GI, DUNCAN ME, O'NEIL P, MCKAY JA, MELVIN WT, FOTHERGILL JE:Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. Pathol. (1998) 185:256–261.
  • MURRAY GI, DUNCAN ME, ONEIL P, MELVIN WT, FOTHERGILL JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. (1996) 2:461–462.
  • •The first demonstration of tumour MMP expression associating with prognosis.
  • NIKKOLA J, VIHINEN P, VLAYKOVA T,HAHKA-KEMPPINEN M, KAHARI VM, PYRHONEN S: High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int. I Cancer (2002) 97:432–438.
  • SUNAMI E, TSUNO N, OSADA T et al.: MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist (2000) 5:108–114.
  • ALLGAYER H, BABIC R, BEYER BC et al.: Prognostic relevance of MMP-2 (72 kD collagenase IV) in gastric cancer. Oncology (Huntingt) (1998) 55:152–160.
  • ONDRUSCHKA C, BUHTZ P, MOTSCH C et al.: Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol. Res. Piaci (2002) 198:509–515.
  • TAKAHASHI M, OKA N, NARODA T et al.: Prognostic significance of matrix metalloproteinases-2 activation ratio in renalcell carcinoma. Urol. (2002)9:531–538.
  • PASSLICK B, SIENEL W,SEEN-HIBLER R et al.: Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin. Cancer Res. (2000) 6:3944–3948.
  • VAISANEN A, KALLIOINEN M, TASKINEN PJ,TURPEENNIEMI-HUJANEN T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J. Pathol. (1998) 186:51–58.
  • INOUE K, KAMADA M, SLATON JW et al.: The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. OM. Cancer Res. (2002) 8:1863–1870.
  • DAVIDSON B, GOLDBERG I, GOTLIEB WH et al.: The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol. Cell Endocrinol. (2002) 187:39–45.
  • SIER CF, KUBBEN FJ, GANESH S et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. Cancer (1996) 74:413–417.
  • YOSHIZAKI T, MARUYAMA Y, SATO H, FURUKAWA M: Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int. J. Cancer (2001) 95:44–50.
  • KANAYAMA H, YOKOTA K, KUROKAWA Y, MURAKAMI Y, NISHITANI M, KAGAWA S:Prognostic values of matrixmetalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer (1998) 82:1359–1366.
  • LIU XP, KAWAUCHI S, OGA A et al.: Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma. fpn. J. Cancer Res. (2002) 93:291–295.
  • MIWA S, MIYAGAWA S, SOEDA J, KAWASAKI S: Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer (2002) 94:428–434.
  • YAMASHITA K, MORI M, SHIRAISHI T, SHIBUTA K, SUGIMACHI K:Clinical significance of matrixmetalloproteinase-7 expression in esophageal carcinoma. Clin. Cancer Res. (2000) 6:1169–1174.
  • YAMAMOTO H, ADACHI Y, ITOH F et al.: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res. (1999) 59:3313–3316.
  • YAMAMOTO H, ITOH F, IKU S et al: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. Chit. Oncol (2001) 19:1118–1127.
  • LAACK E, KOHLER A, KUGLER C et al.: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann. Oncol (2002) 13:1550–1557.
  • SIENEL W, HELLERS J, MORRESI-HAUF A et al: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int. J. Cancer (2003) 103:647–651.
  • YLISIRNIO S, HOYHTYA M, TURPEENNIEMI-HUJANEN T: Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res. (2000) 20:1311–1316.
  • LENGYEL E, SCHMALFELDT B, KONIK E et al: Expression of latent matrix metalloproteinase-9 (MMP-9) predicts survival in advanced ovarian cancer. Cynecol Oncol (2001) 82:291–298.
  • MICHAEL M, BABIC B, KHOKHA R et al.: Expression and prognostic significance of metalloproteinases and their tissueinhibitors in patients with small-cell lung cancer. I Chit. Oncol (1999) 17:1802–1808.
  • BALAZ P, FRIESS H, KONDO Y, ZHU Z, ZIMMERMANN A, BUCHLER MW: Human macrophage metalloelastase worsens the prognosis of pancreatic cancer. Ann. Surg. (2002) 235:519–527.
  • DINGY, SHIMADA Y,GORRIN-RIVAS MJ et al: Clinicopathological significance of human macrophage metalloelastase expression in esophageal squamous cell carcinoma. Oncology (Huntingt.) (2002) 63:378–384.
  • SAKAKIBARA M, KOIZUMI S, SAIKAWA Y et al.: Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer (1999) 85:231–239.
  • MAATTA M, SOINI Y, LIAKKA A, AUTIO-HARMAINEN H:Differential expression of matrix metalloproteinase (IVIMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Chit. Cancer Res. (2000) 6:2726–2734.
  • HANDE K, WILDING G, RIPPLE G: A Phase I study of AG334, a matrix metalloprotease inhibitor, in patients having advanced cancer. Ann. Oncol. (1998) 9\(Suppl. 2):Abstract 279.
  • HEMMINGS FJ, FARHAN M, ROWLAND J, BANKEN L, JAIN R: Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford) (2001) 40:537–543.

Websites

  • http://www.bayerpharma-na.comBAYER CORP.: Bayer Halts Clinical Trials Evaluating MMPI (1999).
  • http://www.sch-plough.com SCHERING-PLOUGH CORP.:Product Pipeline November 2002 (2002).
  • hdp://www.clinicaltrials.govNational Cancer Institute (USA) Clinical Trials Information (2003).
  • http://www.vicc.org/protease Protease Consortium (1999).
  • http://www.signalsmag.com VAN BRUNT J: Rising hopes for new respiratory drugs (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.